Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROPAMIDE versus DYMELOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROPAMIDE versus DYMELOR.
CHLORPROPAMIDE vs DYMELOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, increasing intracellular calcium, and enhancing peripheral insulin sensitivity. Also reduces hepatic glucose production.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx.
Initial: 250 mg orally once daily. Maintenance: 100-500 mg orally once daily.
Initial dose: 250 mg orally once daily with breakfast; maintenance dose: 250-500 mg orally once daily; maximum dose: 1000 mg per day.
None Documented
None Documented
36 hours (range 25-60 hours). Prolonged in renal impairment due to cumulative effects and hypoglycemia risk.
Clinical Note
moderateChlorpropamide + Gatifloxacin
"Chlorpropamide may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateChlorpropamide + Rosoxacin
"Chlorpropamide may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateChlorpropamide + Levofloxacin
"Chlorpropamide may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateChlorpropamide + Trovafloxacin
Terminal elimination half-life is 6-10 hours; clinically significant as it supports once-daily dosing.
Renal excretion of unchanged drug (80-90%) and hepatic metabolites (10-20%). Biliary/fecal excretion is minimal (<5%).
Primarily renal excretion of metabolites and unchanged drug (approximately 70-80%), with biliary/fecal excretion accounting for 10-20%.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic
"Chlorpropamide may increase the hypoglycemic activities of Trovafloxacin."